Anand Patel to Withholding Treatment
This is a "connection" page, showing publications Anand Patel has written about Withholding Treatment.
Connection Strength
0.045
-
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 04 01; 127(7):1039-1048.
Score: 0.045